Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009–2024)

Binbin Cheng(Wenzhou Medical University), Jianjun Chen(Southern Medical University), Xiaopeng Peng(Gannan Medical University), Yingxing Zhou(Hubei Polytechnic University), Wei Wang(Capital Medical University), Jin Liu(Hubei Polytechnic University), Xiaoting Fei(Hubei Polytechnic University), Xian-Shi Ma(People's Hospital of Yangzhong), Wei Pan(Foshan Maternity and Child Health Care Hospital)
European Journal of Medicinal Chemistry
July 1, 2024
10.1016/j.ejmech.2024.116645
Cited by 14

Related Papers

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
|Drug Resistance Updates|2022|257
Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib
|Journal for ImmunoTherapy of Cancer|2020|153
Targeting Piezo1 unleashes innate immunity against cancer and infectious disease
|Science Immunology|2020|151
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
|Pharmacological Reviews|2024|127
Discovery of 2-Hydroxy-<i>N</i>,<i>N</i>-dimethyl-3-{2-[[(<i>R</i>)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123):  A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist
|Journal of Medicinal Chemistry|2006|116